PRDM9 and cancer: Though resistance and secondary cancers have developed, the 2020 approval of Tazemetostat, an EZH2 inhibitor, for relapsed/refractory follicular lymphoma and advanced epithelioid sarcoma marked a significant development in the field by offering a targeted approach against histone methyltransferase dysregulation191.